Markel International appoints Jasminder Kaur as Principal Officer
In her new role, Kaur will be responsible for scaling Markel's operations in Malaysia, one of Southeast Asia's most vibrant economies with an established specialty insurance market. She will collaborate closely with the underwriting team in Singapore, while also working to establish and grow Markel's underwriting capability in Kuala Lumpur. The appointment will build on Markel's existing presence in Malaysia, where Markel is licensed as a Tier 2 reinsurer in Labuan.
Kaur brings close to three decades of experience in the insurance industry, with a strong background in risk management and broking. She most recently served as Chief Executive Officer of MP Honan Insurance Brokers Sdn Bhd, where she played a key role in evolving the local broking firm into an international boutique firm, driving sales growth and operational excellence. Prior to that, she spent more than 8 years at Aon Insurance Brokers Sdn Bhd, where she held various leadership roles, including Chief Broking Officer.
Kaur will report to Kevin Leung, Chief Underwriting Officer – Asia Pacific.
Christian Stobbs, Managing Director - Asia Pacific, commented: "Jasminder's appointment is a key strategic move for our business in Malaysia, leveraging her proven ability to deliver results and her deep understanding of the local market. We're thrilled to have her join our team and are excited about the impact she'll make in leading our expansion efforts and strengthening our relationships with clients and partners."
About Markel Insurance
We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
14 hours ago
- Globe and Mail
1 Brilliant Quantum Computing Stock to Buy Before It Soars 70%, According to 1 Wall Street Analyst
Key Points IonQ is taking a unique approach to quantum computing. Quantum computing is expected to reach a turning point around 2030. 10 stocks we like better than IonQ › Wall Street analysts often give one-year price targets for stocks as a guide to where they think the stock is heading. While these projections are inherently flawed and in no way guarantee what will happen to a stock, understanding what the general analyst community thinks about a stock can be helpful in shaping your own research, especially in an area like quantum computing where there's a lot of hype. Kevin Garrigan from Rosenblatt Security recently set a new price target for quantum computing pure play IonQ (NYSE: IONQ). As of Wednesday's market close, IonQ was trading at $41.21 per share. Garrigan's price target is $70, indicating about 70% upside. That's a strong return in a short time frame, but is IonQ stock a buy now? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » IonQ's trapped ion approach shows potential IonQ is a leading quantum computing company, which is impressive considering that it doesn't have another business to fund its operations. IonQ relies on raising capital in the public markets and various contracts it has to fund its research, unlike many of the big tech competitors in this space, which have massive cash flows to fund their quantum computing research. Despite this disadvantage, IonQ has developed impressive quantum computing technology. IonQ has taken the trapped ion approach to quantum computing, which has benefits and drawbacks. On the plus side, trapped ion architecture has impressive fidelity, and IonQ holds the world record in 1-qubit gate fidelity tests. (A qbit, or quantum bit, is the basic unit of information used in quantum computing to encode data.) It can also be done at room temperature, while other solutions need to be cooled to absolute zero. On the downside, trapped ion quantum computing can have a slightly slower processing speed compared to other solutions. Time will tell whether this is a winning approach, but some of IonQ's early successes indicate that it could be viable. But will that be enough to deliver the $70 stock price that Garrigan thinks is possible? IonQ won't see real business gains for at least a few years Any stock price prediction for IonQ is speculation. While it has a handful of contracts and its quantum computing devices are available for use on all three major cloud computing services, there's really no commercial market for quantum computing right now. However, most quantum computing companies point toward 2030 being a key year, and IonQ is no exception. Its CEO projected that IonQ would be profitable and generate sales of nearly $1 billion by 2030. After that, management expects significant market expansion, with an $87 billion market emerging by 2035. To bridge the gap between profitability and its research phase, IonQ has $1.6 billion in cash, cash equivalents, and outside investments, which should allow it to reach this critical point. While it's impossible to know if IonQ's technology will propel it to be a winning quantum computing pick over the next few years, investors can feel confident that IonQ has the proper resources and backing to at least get to that point. Whether that's worth a $70-per-share target is a different question that I can't answer, but with all of the momentum behind quantum computing, I have a hard time seeing this stock slowing down anytime soon. As a result, I think it's worth an investment, as long as the position size is kept relatively small to help manage risk. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
15 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
